Investigating HLH

About Investigating HLH

Investigating HLH, brought to you by Sobi Inc., is a podcast that takes a deep dive into the complex world of hemophagocytic lymphohistiocytosis, or HLH. As a rare and fatal disease that was once considered incurable, HLH presents with a range of severe signs and symptoms that make diagnosis difficult. Join us as we discuss insights about HLH from all angles with various experts in the field of hematology-oncology who have helped to advance the understanding and treatment of this devastating disease. When treating patients with HLH, knowledge is power—because knowing what to look for can save lives.

Publisher

Sobi Inc.

Category

health & fitness

Language

en

Explicit

No

First episode

14 Nov 2023

Latest episode

23 Sept 2025

Latest episodes

10 episodes in the feed.

1. 

   23 Sept 2025

   What is MAS?

   Adam Narloch speaks with Dr. Daniella Schwartz and Dr. Randy Cron about recognizing and managing MAS, a rare subtype of HLH in rheumatic diseases.

2. 

   25 Feb 2025

   Monitoring Treatment Response

   Kari Magee speaks with Dr Bethany Verkamp to discuss her recent research on evaluating treatment response to etoposide-based treatment in patients with hemophagocytic lymphohistiocytosis (HLH).

3. 

   27 Jun 2024

   A Treatment Option

   Adam Narloch speaks with Dr Michael Jordan to talk about his HLH research and a pivotal trial in HLH. Dr Jordan is a pediatric hematologist-oncologist at Cincinnati Children’s Hospital Medical Center and a professor in the Department of Pediatrics at the University of Cincinnati. Hear from Dr Jordan about his work exploring the pathology of HLH using mouse models, as well as the background, methods, and results from the Gamifant pivotal trial. Indication Gamifant is an interferon gamma (IFNγ)–blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy. Important Safety Information Infections Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB). Prophylaxis for TB should be administered to patients who are at risk for TB or known to have a positive purified protein derivative (PPD) test result or positive IFNγ release assay. Please see additional Important Safety Information and the full Prescribing Information for Gamifant at Gamifant.com. ©2023 Sobi, Inc. All rights reserved. NP-32204 12/23

4. 

   5 Jun 2024

   Treating HLH

   Adam Narloch is joined by Dr. Saara Kaviany and Dr. Blachy J. Dávila Saldaña for a discussion about treating patients with HLH. Dr Kaviany is a pediatric hematologist-oncologist and an assistant professor of pediatrics at University of Chicago Medicine. Dr Saldaña is also a pediatric hematologist-oncologist and an associate professor of pediatrics at George Washington University. Hear from these 2 experts about the overall treatment goals and strategies for patients with HLH. Follow Us YouTube @Sobi-Pharma (https://www.youtube.com/@Sobi-Pharma) Linkedin @Sobi (https://www.linkedin.com/company/sobi/) Presented by Sobi Inc. www.sobi.com (http://www.sobi.com) ©2023 Sobi, Inc. All rights reserved. NP-32204 12/23

5. 

   5 Jun 2024

   Treating Hemophagocytic Lymphohistiocytosis (HLH)

   Dr Saara Kaviany and Dr Blachy J. Dávila Saldaña discuss the overall treatment goals and management strategies for patients with hemophagocytic lymphohistiocytosis (HLH).

6. 

   15 May 2024

   Diagnosing Hemophagocytic Lymphohistiocytosis (HLH)

   Adam Narloch speaks with Dr Ashish Kumar and Dr Scott Canna to discuss the challenges involved with diagnosing and managing hemophagocytic lymphohistiocytosis (HLH).

7. 

   15 May 2024

   Diagnosing HLH

   Adam Narloch speaks with Dr Ashish Kumar and Dr Scott Canna to discuss the challenges involved with diagnosing and managing HLH. Dr Kumar is a pediatric hematologist- oncologist, and a director of the Histiocytosis Center at Cincinnati Children's Hospital. Dr Scott Canna is a pediatric rheumatologist and an Assistant Professor of Pediatrics at Children’s Hospital of Philadelphia. Hear from these 2 experts about why a prompt diagnosis is critical for patients with HLH—and why it can be so difficult to achieve. Follow Us YouTube @Sobi-Pharma (https://www.youtube.com/@Sobi-Pharma) Linkedin @Sobi (https://www.linkedin.com/company/sobi/) Presented by Sobi Inc. https://www.sobi.com/usa/en (https://www.sobi.com/usa/en) ©2023 Sobi, Inc. All rights reserved. NP-32204 12/23

8. 

   22 Apr 2024

   Introduction to HLH

   Adam Narloch speaks with Dr Michelle Hermiston to discuss the history of HLH and advances in understanding this rare disease. Dr Hermiston is a pediatric hematologist-oncologist, a bone marrow transplant specialist, and the director of the Pediatric Immunotherapy Program at UCSF Benioff Children’s Hospital. Join us as we start our journey into the world of HLH! Follow Us YouTube @Sobi-Pharma (https://www.youtube.com/@Sobi-Pharma) Linkedin @Sobi (https://www.linkedin.com/company/sobi/) Presented by Sobi Inc. https://www.sobi.com/usa/en (https://www.sobi.com/usa/en) ©2023 Sobi, Inc. All rights reserved. NP-32204 12/23

9. 

   22 Apr 2024

   An Introduction to Hemophagocytic Lymphohistiocytosis (HLH)

   Adam Narloch speaks with Dr Michelle Hermiston to discuss the history of hemophagocytic lymphohistiocytosis (HLH), advances in clinical understanding, and why recognition of this rare hyperinflammatory syndrome remains important.

10. 

    14 Nov 2023

    An Introduction to HLH

    In this episode of Investigating HLH, Adam Narloch, a Thought Leader Liaison at Sobi, speaks with Dr Michelle Hermiston to discuss the history of HLH and advances that have been made in understanding this rare disease. Dr Hermiston is a pediatric hematologist-oncologist, a bone marrow transplant specialist, and the director of the Pediatric Immunotherapy Program at UCSF Benioff Children’s Hospital. Join us as we start our journey into the world of HLH! Follow Us YouTube @Sobi-Pharma (https://www.youtube.com/c/Sobi-Pharma) LinkedIn @Sobi (https://www.linkedin.com/company/sobi/) Presented by Sobi Inc. https://www.sobi.com/usa/en (https://www.sobi.com/usa/en) ©2023 Sobi, Inc. All rights reserved. NP-32204 12/23

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

4 ratings

Spotify

5.0 / 5

4 ratings

Podcast Authority Score: 10 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

7

Social presence

0

YouTube

0

Engagement

32

Contact Investigating HLH

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.